Comparing the mechanisms by which belinostat and its hydrazide analogs exert anti-cancer effects allows for an assessment of the individual roles of HDAC1 and HDAC3 in the survival of specific leukemia and lymphoma cell types. This evidence concerns the gene HDAC3 and cancer.